Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

University of Sydney

PharmaDeviceNews University of Sydney

Representative image: Targeted prostate cancer treatment enters focus as AstraZeneca’s Truqap approval highlights PTEN-deficient metastatic disease, biomarker testing, and the future of precision oncology.

Pharma & Biotech

Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial

by Pallavi Madhiraju
October 25, 2026
0 Comments

Bayer's NUBEQA improved four-year metastasis-free survival to 95% in high-risk prostate cancer. Overall survival evidence remains immature.

Read More

Latest news and features

CatalYm’s visugromab lifted bladder cancer complete responses to 33%, but can it help patients avoid surgery?
Genmab and Incyte are combining three attacks on KRAS-mutant colorectal cancer, but can they overcome EGFR resistance?
Bayer reports 58% lower metastasis or death risk with NUBEQA in Phase 3 prostate cancer trial
AstraZeneca’s bladder cancer combination cut death risk by 42%, but can it compete with an approved rival regimen?
AstraZeneca and Amgen report 58% lower death risk with IMFINZI and tarlatamab in small-cell lung cancer
Pfizer’s new vaccine targets 25 pneumococcal serotypes, but can it outperform PREVNAR 20?
Genmab’s Rina-S slashed progression risk by 71%, but can it challenge ovarian cancer treatment standards?
Palleon Pharmaceuticals reports rapid remissions with HLX79/E-602 in Phase 2 kidney disease trial
Vopimetostat and daraxonrasib show strong tumor responses as Tango Therapeutics targets Phase 3
Rina-S Phase 3 success brings new hope for platinum-resistant ovarian cancer patients
Roche and Ionis report 43.1% proteinuria reduction with sefaxersen in Phase 3 IgA nephropathy trial
Vertex Pharmaceuticals reports new Phase 3 RAINIER data for povetacicept in IgA nephropathy

POPULAR NEWS

Representative image of oncology biomarker testing and antibody-drug conjugate research. Antengene’s ATG-022 Phase III clearance highlights rising competition in CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer.

Pharma & Biotech

Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab

October 24, 2026

Representative image of a clinician reviewing kidney cancer scans, reflecting Merck & Co., Inc.’s FDA approval of Keytruda and Welireg combinations for adjuvant clear cell renal cell carcinoma treatment.

Pharma & Biotech

Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study

October 24, 2026

Representative image of researchers examining Alzheimer’s disease biomarker data as NeuroSense evaluates PrimeC’s multi-target potential in a small exploratory study.

Pharma & Biotech

NeuroSense links PrimeC to Alzheimer’s biomarkers, but can three patients justify another trial?

June 26, 2026

Latest business and industry news

UAE closes Umm Al Quwain beaches after tanker oil spill threatens Gulf coastline
Leland Little Auctions establishes Charleston office to strengthen its Southeast collecting network
Confido Health secures $22.5m Series A funding as CareOS moves beyond voice AI
Italian wine exports rebound 17% in the U.S., but Vinitaly.USA arrives as actual sales remain weak
REJURAN Cosmetics enters Costco’s new Beauty Table program, but can PDRN skincare convert attention into repeat sales?

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.